2009-07-14

Göteborg – Sweden – July 14 2009 – PharmaSurgics AB. successfully completes Phase I clinical study showing their novel candidate drug PXL01 is safe and well tolerated. Initially developed to prevent post-surgical adhesion formation following hand surgery the product combines the pharmacological effect of PXL01 with the physical barrier effect of the vehicle, and has the potential to be the first anti-adhesion drug on the market. ‘These results provide the foundation for proceeding to the next phase, proof of concept study in patients’ said Fredrik Sjövall, CEO of PharmaSurgics, adding ‘the proof of concept study in patients of flexor tendon repair surgery is scheduled to start in December 2009.’

Post-surgical adhesions are bands of scar tissue connecting anatomic sites in the body that should not normally be connected. These develop after almost every type of surgery and cause symptoms such as restricted joint mobility, chronic pain, intestinal obstruction and re-operative complications. Following flexor tendon repair surgery post-surgical adhesions lead to decreased strength and function of the affected joints, extensive postoperative physiotherapy and extended periods of sick leave.

About PharmaSurgics

PharmaSurgics in Sweden AB is a Gothenburg based biotech company that develops and commercializes a novel treatment for preventing harmful scarring and promoting wound healing after surgery. PharmaSurgics product concept is based on proprietary synthetic peptides which have strong anti-inflammatory and antiinfectious properties. The company was founded in 2005, based on extensive research by Dr. Inger Mattsby-Baltzer and Professor Kjell Olmarker at Sahlgrenska University Hospital, Göteborg, Sweden. PharmaSurgics is a Karolinska Development portfolio company.

For further information please contact:
Fredrik Sjövall, CEO of PharmaSurgics
Ph: +46 31 762 29 01
Email: fredrik@pharmasurgics.se

Complete press release